Overcoming Barriers to Treatment in Metastatic HNSCC:
Strategies to Manage Adverse Events
Associated with Immunotherapies


A continuing medical education activity sponsored by NAMCP and AAMCN.

New Horizons in the Treatment of Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC):
How Immunotherapies Are Changing the Treatment Paradigm

This is Part III of the series focusing on Barriers to Treatment in Metastatic HNSCC

This activity is an archive from the webinar held September 13, 2017. If you participated
in the live webinar, you are not eligible for credits for this activity.

This activity is valid from November 1, 2017 to November 30, 2018

Instructions for CME/CNE: Complete the pre test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Merck Sharp & Dohme Corp

Description:
Head and neck squamous cell carcinoma (HNSCC) represents a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 48,330 new cases are diagnosed annually in the United States, and 9,570 people die of the disease. HNSCC historically has been associated with tobacco and alcohol use; however, during the past decade, infection with high-risk human papillomavirus (HPV) has been implicated in the pathogenesis of a growing subset of HNSCCs. Despite advances and innovations in multimodality treatment and a better understanding of head and neck carcinogenesis, survival rates of locally metastatic HNSCC have not substantially improved, and the prognosis for recurrent/metastatic disease remains poor. Fortunately for patients with metastatic HNSCC, new immunotherapeutic options, which have shown improved efficacy and safety, have recently become available to give clinicians and managed care professionals more options when managing a population of metastatic HNSCC patients. This webinar will be part three of a four-part webinar series, and it will look closely at overcoming barriers to treatment in metastatic HNSCC, with a close look and managing immune-related adverse events.

Upon Completion of this activity, participants will be able to:

  • Discuss challenges and barriers that healthcare professionals face when managing metastatic HNSCC

  • Identify adverse events commonly associated with immunotherapeutic agents used in the treatment of metastatic HNSCC

  • Discuss strategies to mitigate side effects related to treatment with immunotherapeutic agents in patients with metastatic HNSCC

  • Assess the informational needs of patients and families/caregivers regarding their treatment plan and identify methods to counsel them

  • Review how treatment strategies can be affected by adverse events based on patient’s individualized needs
     

Faculty: Robert L. Ferris, MD, PhD
Professor and Chief, Division of Head and Neck Surgery, Departments of Otolaryngology, Radiation Oncology, and Immunology; Co-leader, Cancer Immunology Program
UPMC Hillman Cancer Center

Disclosure:

Dr. Ferris serves as an advisor for Amgen, AstraZeneca/MedImmune, Bristol-Myers Squibb, EMD Serono, PPD (Benetic), Lilly, Merck, and Pfizer. He has received and or receives research support from AstraZeneca/MedImmune, Bristol-Myers Squibb, VentiRx Pharmaceuticals. Dr. Ferris also received clinical trial funding from AstraZeneca/MedImmune, Bristol-Myers Squibb, and Merck. His presentation has been peer reviewed for any bias.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Merck Sharp & Dohme Corp

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue